In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 month
Objective: Peroxisome proliferator-activated receptor γ(PPARγ) plays a critical role in adipocyte differ-entiation and the development of type 2 diabetes mel